Teva hits major biosimilar milestones with FDA nod and regulatory filings
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
It promises fewer injections for vision loss patients
Call it a major breakthrough for diagnostic imaging
Subscribe To Our Newsletter & Stay Updated